Thursday, April 30, 2020
Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System™, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms. The Contour Neurovascular System™ is a unique, fine mesh braid that is deployed across the neck of the aneurysm sac and provides a combination of flow diversion and flow disruption through a single device implant. This new, lower profile system will allow physicians to access more distally challenging vascular anatomies.
"In response to numerous requests from the clinical community and physicians we work closely with, we continue to aggressively expand our product portfolio to offer an even more comprehensive suite of products to meet market needs, complementing our Contour 027 device and Neqstent™ platform, which recently received CE Mark approval," stated Dr. Stephen Griffin, President of Cerus Endovascular.
"This latest approval testifies to the strength of our product pipeline and represents another critical step in our go-to-market strategy via a controlled roll-out," stated Dr. Sam Milstein, Chairman of Cerus Endovascular. "We look forward to initiating sales later this year and are pleased to be able to offer the medical community additional, key solutions that will meaningfully benefit patient care."
